Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475775 | 0.90 | MEN1 (0.56) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL5219444 | 0.90 | MEN1 (0.56) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL5220854 | 0.90 | MEN1 (0.46) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL5099773 | 0.86 | PKM (0.50) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL5221306 | 0.86 | ALDH1A1 (0.58) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL6185617 | 0.85 | ALDH1A1 (0.61) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL5221028 | 0.85 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL5219191 | 0.84 | CA12 (0.53) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL5241791 | 0.84 | MEN1 (0.51) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL2533613 | 0.84 | MEN1 (0.51) | MEN1KMT2AALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591317-A | P2X3 inhibitors and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| US-6992103-B2 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-31 | — | — | US | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-04-21 | — | — | US | disclosed |
| WO-2004111022-A1 | 3-(1,1-DIOXOTETRAHYDRO-1,2-THIAZIN-2-YL) or 3-(1,1-DOXO-ISOTHIAZOLIDIN-2YL) SUBSTITUTED BENZAMIDE COMPOUNDS AS ASP2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| EP-1448520-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| WO-2003045913-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | BACE2, PSEN2, BACE1 | MEN1 498/4885KMT2A 955/4885ALDH1A1 1848/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | MEN1 586/4885KMT2A 300/4885ALDH1A1 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.